- Vertex earnings get muted investor response<p>While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.</p>BioPharma Dive · 2mo ago↗ source
- Cytokinetics heart drug scores in closely watched trial<figure><div><img src="https://imgproxy.divecdn.com/O5l3Ak2w-ITPZwAy2_UP-yuYAxNqpRx2E-yOxBQdi8M/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy05MzA1MTIzNTAuanBn.…BioPharma Dive · 2mo ago↗ source
- <![CDATA[New Endometrial Targets Beyond HER2]]><![CDATA[Interest in endometrial cancer extends well beyond HER2, and the faculty review a growing pipeline of antibody drug conjugates directed at additional targets. Discussion includes why TROPE…